Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species

Sho Ichi Yamagishi, Takanori Matsui, Kazuo Nakamura, Hiroyoshi Inoue, Masayoshi Takeuchi, Seiji Ueda, Seiya Okuda, Tsutomu Imaizumi

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Background/Aims: We have previously shown that interaction between advanced glycation end products (AGEs) and their receptor (RAGE) evokes generation of reactive oxygen species (ROS) and subsequently vascular inflammation, thus being involved in the development of diabetic retinopathy. Since there is crosstalk between the AGE-RAGE axis and the renin-angiotensin system in the pathogenesis of early diabetic retinopathy, we investigated in this study whether olmesartan, an angiotensin II type 1 receptor blocker, inhibited the AGE-evoked inflammatory reactions in endothelial cells (ECs) by suppressing ROS generation. Methods: ROS generation was evaluated by dihydroethidium staining. Gene and protein expression were analyzed by reverse-transcription polymerase chain reaction and ELISA, respectively. Results: Olmesartan significantly inhibited the AGE-evoked ROS generation and reduced the expression levels of monocyte chemoattractant protein 1 in microvascular ECs. Olme-sartan also suppressed intercellular-adhesion molecule 1 expression in, and subsequently blocked T-cell adhesion to, AGE-exposed ECs. Conclusions: The present study demonstrates for the first time that olmesartan inhibits AGE-evoked inflammatory reactions in ECs by suppressing ROS generation. Blockade of the renin-angiotensin system by olmesartan may play a protective role against diabetic retinopathy by attenuating the deleterious effects of AGEs through its antioxidative properties.

Original languageEnglish
Pages (from-to)10-15
Number of pages6
JournalOphthalmic Research
Volume40
Issue number1
DOIs
Publication statusPublished - 2007 Dec
Externally publishedYes

Fingerprint

Advanced Glycosylation End Products
Reactive Oxygen Species
Endothelial Cells
Diabetic Retinopathy
Angiotensin II Type 1 Receptor Blockers
Renin-Angiotensin System
Chemokine CCL2
Intercellular Adhesion Molecule-1
Cell Adhesion
Reverse Transcription
Blood Vessels
Enzyme-Linked Immunosorbent Assay
olmesartan
Staining and Labeling
Inflammation
T-Lymphocytes
Gene Expression
Polymerase Chain Reaction
Proteins

Keywords

  • Advanced glycation end products
  • Angiotensin II
  • Diabetic retinopathy
  • Intercellular adhesion molecule 1
  • Monocyte chemoattractant protein 1
  • Olmesartan
  • Reactive oxygen species

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species. / Yamagishi, Sho Ichi; Matsui, Takanori; Nakamura, Kazuo; Inoue, Hiroyoshi; Takeuchi, Masayoshi; Ueda, Seiji; Okuda, Seiya; Imaizumi, Tsutomu.

In: Ophthalmic Research, Vol. 40, No. 1, 12.2007, p. 10-15.

Research output: Contribution to journalArticle

Yamagishi, Sho Ichi ; Matsui, Takanori ; Nakamura, Kazuo ; Inoue, Hiroyoshi ; Takeuchi, Masayoshi ; Ueda, Seiji ; Okuda, Seiya ; Imaizumi, Tsutomu. / Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species. In: Ophthalmic Research. 2007 ; Vol. 40, No. 1. pp. 10-15.
@article{c36ff6b4dbb544ddab95a6c40c5c8b18,
title = "Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species",
abstract = "Background/Aims: We have previously shown that interaction between advanced glycation end products (AGEs) and their receptor (RAGE) evokes generation of reactive oxygen species (ROS) and subsequently vascular inflammation, thus being involved in the development of diabetic retinopathy. Since there is crosstalk between the AGE-RAGE axis and the renin-angiotensin system in the pathogenesis of early diabetic retinopathy, we investigated in this study whether olmesartan, an angiotensin II type 1 receptor blocker, inhibited the AGE-evoked inflammatory reactions in endothelial cells (ECs) by suppressing ROS generation. Methods: ROS generation was evaluated by dihydroethidium staining. Gene and protein expression were analyzed by reverse-transcription polymerase chain reaction and ELISA, respectively. Results: Olmesartan significantly inhibited the AGE-evoked ROS generation and reduced the expression levels of monocyte chemoattractant protein 1 in microvascular ECs. Olme-sartan also suppressed intercellular-adhesion molecule 1 expression in, and subsequently blocked T-cell adhesion to, AGE-exposed ECs. Conclusions: The present study demonstrates for the first time that olmesartan inhibits AGE-evoked inflammatory reactions in ECs by suppressing ROS generation. Blockade of the renin-angiotensin system by olmesartan may play a protective role against diabetic retinopathy by attenuating the deleterious effects of AGEs through its antioxidative properties.",
keywords = "Advanced glycation end products, Angiotensin II, Diabetic retinopathy, Intercellular adhesion molecule 1, Monocyte chemoattractant protein 1, Olmesartan, Reactive oxygen species",
author = "Yamagishi, {Sho Ichi} and Takanori Matsui and Kazuo Nakamura and Hiroyoshi Inoue and Masayoshi Takeuchi and Seiji Ueda and Seiya Okuda and Tsutomu Imaizumi",
year = "2007",
month = "12",
doi = "10.1159/000111152",
language = "English",
volume = "40",
pages = "10--15",
journal = "Ophthalmic Research",
issn = "0030-3747",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species

AU - Yamagishi, Sho Ichi

AU - Matsui, Takanori

AU - Nakamura, Kazuo

AU - Inoue, Hiroyoshi

AU - Takeuchi, Masayoshi

AU - Ueda, Seiji

AU - Okuda, Seiya

AU - Imaizumi, Tsutomu

PY - 2007/12

Y1 - 2007/12

N2 - Background/Aims: We have previously shown that interaction between advanced glycation end products (AGEs) and their receptor (RAGE) evokes generation of reactive oxygen species (ROS) and subsequently vascular inflammation, thus being involved in the development of diabetic retinopathy. Since there is crosstalk between the AGE-RAGE axis and the renin-angiotensin system in the pathogenesis of early diabetic retinopathy, we investigated in this study whether olmesartan, an angiotensin II type 1 receptor blocker, inhibited the AGE-evoked inflammatory reactions in endothelial cells (ECs) by suppressing ROS generation. Methods: ROS generation was evaluated by dihydroethidium staining. Gene and protein expression were analyzed by reverse-transcription polymerase chain reaction and ELISA, respectively. Results: Olmesartan significantly inhibited the AGE-evoked ROS generation and reduced the expression levels of monocyte chemoattractant protein 1 in microvascular ECs. Olme-sartan also suppressed intercellular-adhesion molecule 1 expression in, and subsequently blocked T-cell adhesion to, AGE-exposed ECs. Conclusions: The present study demonstrates for the first time that olmesartan inhibits AGE-evoked inflammatory reactions in ECs by suppressing ROS generation. Blockade of the renin-angiotensin system by olmesartan may play a protective role against diabetic retinopathy by attenuating the deleterious effects of AGEs through its antioxidative properties.

AB - Background/Aims: We have previously shown that interaction between advanced glycation end products (AGEs) and their receptor (RAGE) evokes generation of reactive oxygen species (ROS) and subsequently vascular inflammation, thus being involved in the development of diabetic retinopathy. Since there is crosstalk between the AGE-RAGE axis and the renin-angiotensin system in the pathogenesis of early diabetic retinopathy, we investigated in this study whether olmesartan, an angiotensin II type 1 receptor blocker, inhibited the AGE-evoked inflammatory reactions in endothelial cells (ECs) by suppressing ROS generation. Methods: ROS generation was evaluated by dihydroethidium staining. Gene and protein expression were analyzed by reverse-transcription polymerase chain reaction and ELISA, respectively. Results: Olmesartan significantly inhibited the AGE-evoked ROS generation and reduced the expression levels of monocyte chemoattractant protein 1 in microvascular ECs. Olme-sartan also suppressed intercellular-adhesion molecule 1 expression in, and subsequently blocked T-cell adhesion to, AGE-exposed ECs. Conclusions: The present study demonstrates for the first time that olmesartan inhibits AGE-evoked inflammatory reactions in ECs by suppressing ROS generation. Blockade of the renin-angiotensin system by olmesartan may play a protective role against diabetic retinopathy by attenuating the deleterious effects of AGEs through its antioxidative properties.

KW - Advanced glycation end products

KW - Angiotensin II

KW - Diabetic retinopathy

KW - Intercellular adhesion molecule 1

KW - Monocyte chemoattractant protein 1

KW - Olmesartan

KW - Reactive oxygen species

UR - http://www.scopus.com/inward/record.url?scp=37349025554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349025554&partnerID=8YFLogxK

U2 - 10.1159/000111152

DO - 10.1159/000111152

M3 - Article

C2 - 18025836

AN - SCOPUS:37349025554

VL - 40

SP - 10

EP - 15

JO - Ophthalmic Research

JF - Ophthalmic Research

SN - 0030-3747

IS - 1

ER -